U.S., Jan. 21 -- ClinicalTrials.gov registry received information related to the study (NCT03803605) titled 'Study to Assess Safety and Activity of Combination Therapy of VRC07-523LS and Vorinostat on HIV-infected Persons' on Jan. 10.
Brief Summary: Adult participants (18-64 years old) with HIV-1 Infection on cART with a CD4 T cell count >= 350 cells/mm3 and viral suppression for >= 24 months will be enrolled on this study. Participants will receive two series of combination therapy consisting of one (1) intravenous (IV) dose of VRC-HIVMAB075-00-AB (VRC07-523LS) followed by 10 oral (PO) doses of Vorinostat (VOR) taken every 72 hours. Each series will last approximately 1 month and the two series will be separated by at least one month. Com...